Recent Updates
Recently added Catalysts

Adefovir dipivoxil

Phase 2

Hepatitis B | Small molecule | Infectious Disease |Gilead Sciences, Inc.|Last Updated: Aug 10, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLEDBiomarker
Total Trials3
Total Enrollment79
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00644761PK Study of Tacrolimus and Cyclosporine When Co-Administered With Adefovir Dipivoxil in Post-Liver Transplant PatientsPHASE2 COMPLETED 16Feb 1, 2004May 1, 2005Apr 10, 200811 United States
NCT01146808Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive LiverPHASE1 COMPLETED 16Mar 1, 2006Sep 1, 2012Aug 10, 20211 United States
NCT00645294Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBVPHASE1 COMPLETED 47Feb 1, 2003Aug 1, 2003Mar 27, 200810 Belgium, Germany +2
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
To evaluate pharmacokinetics of tacrolimus or cyclosporine when co-administered with adefovir dipivoxil 10 mg once daily to patients post-liver transplantation
21 days
Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver
Standard of care visits post-transplant for 2 years

Determined by positive hepatitis B serology (tests positive for HBsAg) and HBV DNA viral load (\>40 IU/mL).

To characterize the PK profile of adefovir 0.14 mg/kg and 0.3 mg/kg in children 2-11 years, including dose proportionality of adefovir dipivoxil liquid formulation. To characterize the PK profile of adefovir dipivoxil 10 mg in adoloscents 12-17 years.
8 days
Secondary Endpoints
To evaluate PK of ADV 10 mg once daily when co-administered with tacrolimus or cyclosporine in patients post-liver transplantation. To evaluate the safety of ADV 10 mg once daily, when co-administered with tacrolimus or cyclosporine for 14 days.
21 days
Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer > 500 IU/mL Prior to and After Vaccination
12-18 months post transplant
Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal
Six months after hepatitis B vaccination (2 years post transplant)
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Treatment Arm 1OTHERAdefovir dipivoxil 10 mg once daily with tacrolimus or cyclosporine for 14 days
ADV plus hepatitis B vaccinationEXPERIMENTALAdefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.
Treatment Group AOTHERADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
Treatment Group BOTHERADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
Treatment Group COTHERADV 10 mg single dose on Day 1 in 12-17 year old age group
Interventions
NameTypeDescription
Adefovir DipivoxilDRUGAdefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
Adefovir dipivoxil and hepatitis B vaccinationDRUGAdefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersNo
Study Sites11

Inclusion Criteria: * 18-65 years of age * Greater than or equal to 6 months post-liver transplantation * Must be on a documented stable total daily dose of tacrolimus or cyclosporine for three months. * Must have calculated creatinine clearance greater than or equal 50 mL/min (Cockcroft-Gault meth...

Countries:United StatesBelgiumGermanyPolandUnited Kingdom
Unlock Eligibility Criteria